A widely used osteoporosis drug is safer and just as effective reducing invasive breast cancer risk as tamoxifen, the only drug now approved for that use, say long-awaited data released Monday from a trial of nearly 20,000 women.
The drug is called raloxifene and fights breast cancer as well as taxmoxifen with fewer side effects.
No comments:
Post a Comment